Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 2
2003 4
2004 2
2005 5
2006 8
2007 9
2008 4
2009 4
2010 2
2011 4
2012 5
2013 1
2014 3
2015 3
2016 2
2017 3
2018 7
2019 3
2020 8
2021 2
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Results by year

Filters applied: . Clear all
Page 1
IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies.
Leborgne C, Barbon E, Alexander JM, Hanby H, Delignat S, Cohen DM, Collaud F, Muraleetharan S, Lupo D, Silverberg J, Huang K, van Wittengerghe L, Marolleau B, Miranda A, Fabiano A, Daventure V, Beck H, Anguela XM, Ronzitti G, Armour SM, Lacroix-Desmazes S, Mingozzi F. Leborgne C, et al. Among authors: delignat s. Nat Med. 2020 Jul;26(7):1096-1101. doi: 10.1038/s41591-020-0911-7. Epub 2020 Jun 1. Nat Med. 2020. PMID: 32483358 Free article.
Imlifidase, a new option to optimize the management of patients with hemophilia A on emicizumab.
Bou-Jaoudeh M, Mimoun A, Delignat S, Peyron I, Capdevila L, Daventure V, Deligne C, Dimitrov JD, Christophe OD, Denis CV, Lenting PJ, Proulle V, Lacroix-Desmazes S. Bou-Jaoudeh M, et al. Among authors: delignat s. J Thromb Haemost. 2023 Oct;21(10):2776-2783. doi: 10.1016/j.jtha.2023.06.038. Epub 2023 Jul 18. J Thromb Haemost. 2023. PMID: 37473843 Free article.
Immunogenicity of long-lasting recombinant factor VIII products.
Ing M, Gupta N, Teyssandier M, Maillère B, Pallardy M, Delignat S, Lacroix-Desmazes S; ABIRISK consortium. Ing M, et al. Among authors: delignat s. Cell Immunol. 2016 Mar;301:40-8. doi: 10.1016/j.cellimm.2015.12.006. Epub 2015 Dec 19. Cell Immunol. 2016. PMID: 26723503 Free article. Review.
Dendritic cells and autoimmunity.
Bayry J, Thirion M, Delignat S, Misra N, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV. Bayry J, et al. Among authors: delignat s. Autoimmun Rev. 2004 Mar;3(3):183-7. doi: 10.1016/S1568-9972(03)00104-6. Autoimmun Rev. 2004. PMID: 15110229 Review.
Pathophysiology of catalytic antibodies.
Lacroix-Desmazes S, Wootla B, Delignat S, Dasgupta S, Nagaraja V, Kazatchkine MD, Kaveri SV. Lacroix-Desmazes S, et al. Among authors: delignat s. Immunol Lett. 2006 Feb 28;103(1):3-7. doi: 10.1016/j.imlet.2005.10.007. Epub 2005 Nov 2. Immunol Lett. 2006. PMID: 16427704 Review.
Transplacental delivery of therapeutic proteins by engineered immunoglobulin G: a step toward perinatal replacement therapy.
Mimoun A, Bou-Jaoudeh M, Delignat S, Daventure V, Reyes Ruiz A, Lecerf M, Azam A, Noe R, Peyron I, Christophe OD, Lenting PJ, Proulle V, McIntosh J, Nathwani AC, Dimitrov JD, Denis CV, Lacroix-Desmazes S. Mimoun A, et al. Among authors: delignat s. J Thromb Haemost. 2023 Sep;21(9):2405-2417. doi: 10.1016/j.jtha.2023.05.021. Epub 2023 Jun 2. J Thromb Haemost. 2023. PMID: 37271431
73 results